货号 | AF1555-SP |
别名 | CDKN1B; CDKN4; cyclin-dependent kinase inhibitor 1B (p27, Kip1); cyclin-dependent kinase inhibitor 1B; Cyclin-dependent kinase inhibitor p27; Kip1; KIP1P27KIP1; MEN1B; MEN4; p27Kip1 | 全称 | p27 Cyclin Dependent Kinase 4 Inhibitor 1B |
应用 | Western Blot(0.5 µg/mL) |
目标/特异性 | Reconstitute at 0.2 mg/mL in sterile PBS. |
使用方法 | Western Blot: 0.5 µg/mL |
来源 | Polyclonal Rabbit IgG |
产品组分 |
供应商 | R&D Systems |
Entrez Gene IDs | 1027 (Human); 12576 (Mouse); 83571 (Rat) |
应用文献 | |
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. Cytoplasmic p27 promotes epithelial-mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation. | |
纯化方式 | Antigen Affinity-purified |
免疫原 | Phosphopeptide containing human p27/Kip1 T157 site |
生物活性 | Human |
标记 | Unconjugated |
溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
背景 | The cyclin-dependent kinase (cdk) inhibitor p27/Kip1 is a tumor suppressor protein that acts in the nucleus to enforce cell cycle checkpoints. The Akt protein kinase phosphorylates T157, an amino acid residue that lies within a nuclear localization signal for p27, to prevent nuclear localization and thus preclude the growth inhibitory function of p27. |
运输条件 | Blue Ice |
存放说明 | 4℃ |
参考文献 |
|
Detection of Human Phospho-p27/Kip1 (T157) by Western Blot. Western blot shows lysates of MCF-7 human breast cancer cell line untreated (-) or treated (+) with 100 ng/mL Recombinant Human IGF-I (Catalog # 291‑G1) for 20 minutes. PVDF membrane was probed with 0.5 µg/mL Human Phospho-p27/Kip1 (T157) Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1555) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). A specific band for Phospho-p27/Kip1 (T157) was detected at approximately 27 kDa (as indicated). The phospho-specificity of this antibody was supported by decreased labeling following treatment with 600 U lambda -phosphatase ( lambda -PPase) for 1 hour. This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1. |